
Your submission to Biomed. Phys. Eng. Express: BPEX-101752

4 pesan

Biomedical Physics & Engineering Express <onbehalf@manuscriptcentral.com>

13 November 2019 pukul
16.05

Balas Ke: bpex@iopublishing.org

Kepada: herisutanto@fisika.undip.ac.id, yulia.irdawati.2018@fisika.fsm.undip.ac.id, anam@fisika.undip.ac.id, ekohidayanto@fisika.undip.ac.id, zaenalarifin@fisika.undip.ac.id, fujibuch@hs.med.kyushu-u.ac.jp, Geoff.Dougherty@csuci.edu, jwsono@metal.ui.ac.id, bahruddin@lecturer.unri.ac.id

Dear Dr Sutanto,

Re: "An artifact-free thyroid shield in CT examination: a phantom study" by Sutanto, Heri; Irdawati, Yulia; Anam, Choirul; Hidayanto, Eko; Arifin, Zaenal; Fujibuchi, Toshio; Dougherty, Geoff; Soedarsono, Johni; Bahruddin, Bahruddin

Article reference: BPEX-101752

Thank you for submitting your Paper, which will be considered for publication in Biomedical Physics & Engineering Express. The reference number for your article is BPEX-101752. Please quote this number in all future correspondence regarding this manuscript.

As the submitting author, you can follow the progress of your article by checking your Author Centre after logging in to <https://mc04.manuscriptcentral.com/bpex-iop> Once you are signed in you will be able to track the progress of your article, read the referee reports and send us your electronic files.

This journal makes manuscripts available to readers on the journal website within 24 hours of acceptance. Please be aware that if you did not tick the relevant opt-out box on the submission form, the accepted version of your manuscript will be visible on the journal's website before it is proof-read and formatted to our house style.

If you are planning any press activity for your article, or are currently engaging in an IP or patent application, you may wish to opt-out of making your accepted manuscript immediately available online. If you do not wish to make the accepted version of your manuscript immediately visible to readers, and have not ticked the opt-out box during submission, please let us know as soon as possible.

Please do not hesitate to contact us if we can be of assistance to you.

Yours sincerely

On behalf of the IOP peer-review team:

Jade Holt - Managing Editor

Maddy Cumbes - Associate Editor

Blythe Rowley & Jo Bewley - Editorial Assistants

Want to find out what is happening to your submission right now? Track your article here: https://publishingsupport.iopscience.iop.org/track-my-article/?utm_source=Track%20my%20article&utm_medium=Email

bpex@iopublishing.org

Robert Jeraj - Editor-in-Chief

Lauren Carter - Publisher

IOP Publishing

Temple Circus, Temple Way, Bristol, BS1 6HG, UK

www.iopscience.org/bpex

1 An artifact-free thyroid shield in CT examination: a phantom study

2 Heri Sutanto^{1,*}, Yulia Irdawati¹, Choirul Anam¹, Toshioh Fujibuchi², Geoff Dougherty³, Eko
3 Hidayanto¹, Zaenal Arifin¹, Johny Wahyuadi Soedarsono⁴, Bahrudin⁵

4 ¹ Department of Physics, Faculty of Sciences and Mathematics, Diponegoro University, Jl. Prof.
5 Soedarto SH, Tembalang, Semarang 50275, Central Java, Indonesia

6 ² Department of Health Sciences, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi,
7 Higashi-Ku, Fukuoka 812-8582, Japan

8 ³ Department of Applied Physics and Medical Imaging, California State University Channel Islands,
9 Camarillo, CA 93012, USA

10 ⁴ Department of Metallurgical and Materials Engineering, University of Indonesia, Depok 16424,
11 Indonesia

12 ⁵ Department of Chemical Engineering, University of Riau, Pekanbaru 28293, Indonesia

13
14 Corresponding author: herisutanto@live.undip.ac.id

15 Abstract

16 This study was to evaluate dose reduction and resulting image quality of a new synthetic thyroid shield
17 based on silicon rubber (SR)–lead (Pb) composites and compare to tungsten paper (WP) and a
18 Radibarrier thyroid shields in CT examination of the neck. The synthetic SR-Pb thyroid shield had a
19 Pb percentage from 0 to 5 wt% and a thickness of 0.6 cm. Scanning on the neck of an anthropomorphic
20 phantom was performed with and without the SR-Pb, WP, and Radibarrier thyroid shields. The thyroid
21 shields were placed directly on the neck surface. The thyroid dose was measured using radiophoto-
22 luminescence (RPL) detectors. Image quality was characterized by consistency of the Hounsfield unit
23 (HU) on the areas of anterior, posterior and lateral of the neck phantom. Detailed evaluation of the
24 image quality was employed by image subtraction. It was found that the thyroid dose at the surface
25 decreased with an increase of Pb percentage in the SR-Pb shield. The thyroid dose reduction was 34%
26 for a Pb percentage of 5 wt%. The reduction of the dose using WP and Radibarrier were 36% and 67%,
27 respectively. The dose reduction when using the WP and Radibarrier was higher than when using the
28 SR-Pb 5 wt% thyroid shield. However the existence of artifact in the WP and the Radibarrier reduced
29 the image quality, indicated by a significant change of HU, i.e. the increases of HU in the posterior area
30 were 77% for the WP and 553% for the Radibarrier. The SR-Pb shield produced only a very small
31 artifact, resulting in an increase of HU in the posterior area of only 9%. The SR-Pb shield is suitable
32 in the daily clinical setting for thyroid dose reduction in CT examinations while maintaining image quality.

34 Introduction

35 Computed tomography (CT) provides excellent images for diagnosing patient abnormalities
36 [1], however the dose received by radiosensitive organs, specifically to the superficial organs
37 such as the thyroid, gonads, eye lens and breast, is a significant concern [2-12]. These organs
38 are composed of radiosensitive cells and have a greater risk of developing cancer in the future
39 [4, 6, 10, 11, 13-17]. Among the most frequent CT examinations are head, thorax, cervical
40 spine and neck. In these CT examinations, the thyroid glands is often exposed to the primary
41 beam and receives high dose [6-8,17,18]. The International Commission on Radiological
42 Protection (ICRP) reported that the thyroid has a tissue weighting factor (W_T) of 0.04, meaning
43 that the risk is very high [19, 20]. Therefore, it is crucial to reduce the dose received by the
44 thyroid as much as possible while maintaining image quality [19, 20]. Dose optimization
45 should be kept in mind because of the inverse relationship between good image quality and
46 low radiation doses [4, 21-23].

1
2
3 47 A straightforward method to optimize thyroid dose and image quality in the CT examination is using a
4 48 thyroid shield which is commercially available and is based on bismuth-latex [24]. Gbelcova et al. [25]
5 49 reported that the reduction of dose by a thyroid shield is in the range from 23% to 35%. This agrees
6 50 with other studies reporting thyroid dose reductions from 25 to 40% [18, 26, 27]. However, the main
7 51 limitation of the bismuth shield is that it causes artifact in the image, especially in areas close to the
8 52 thyroid shield, due to the x-ray transmissions that are supposed to contribute to the image which are
9 53 absorbed by the material of the thyroid shield itself [10, 24, 28].

11 54 Currently, a common strategy to optimize the thyroid dose by automatic tube current modulation
12 55 (ATCM) [29]. Hoang et al. [18] reported that by using ATCM, thyroid dose decreased by up to 29.5%
13 56 and there was no significant degradation of image quality. The similar results were also reported
14 57 elsewhere [18, 26, 27]. A combination of ATCM and thyroid shield will further increase a dose
15 58 reduction. Inkoom et al. [28] reported that combination of both can increase the reduction of thyroid
16 59 dose from 22.5% to 78%. However, many studied reported that a combination of both causes
17 60 unpredictable dose result when thyroid shield is located before scanning of scout [20, 22]. The dose
18 61 reduction is difficult to evaluate, because ATCM depends on the region scanned and patient body
19 62 habitus and is affected by thyroid shield [21, 30-32]. Nowadays, the ATCM is commonly used in the
20 63 most modern CT, however, it should be noted that not all CT scans are equipped with ATCM feature.

22 64 Correspondingly, based on these available strategies, thyroid shield remains the choice for CT scan that
23 65 is not featured with ATCM or to be used as combination with ATCM. Most thyroid shields are made
24 66 from Bismuth-latex, because of its high atomic number ($Z = 83$) and consequent high ability to absorb
25 67 radiation [33]. To minimize the artifact of the resulting image caused by the thyroid shield, many studies
26 68 recommend a spacer from 1 to 3 cm between the thyroid shield and the neck [6, 18, 34]. By adding
27 69 distance, it was reported there is no significant change in HU values with and without thyroid shield.
28 70 However, an addition of a spacer may be time-consuming and prolong examination time in the clinical
29 71 practice. Therefore, efforts to develop a new thyroid shield that can effectively reduce doses while
30 72 minimizing or even removing the artifacts need to be considered.

32 73 Recently Irdawati et al. [35] proposed a new material for superficial organ shield based on silicon rubber
33 74 (SR) and lead (Pb). It was reported that the SR-Pb has a good ability as an eye shield with a dose
34 75 reduction up to 50% without any artifact appearing in the image even though it is placed directly on the
35 76 organ surface [35]. Although SR-Pb is a promising material as a superficial organ shield, it has not
36 77 applied to any other organ other than the eye lens. The aim of this study, therefore, was to investigate
37 78 the ability of a SR-Pb shield, placed directly on the neck surface, to reduce the dose to the thyroid during
38 79 CT neck examination. We compared it to other thyroid shields such as Tungsten Paper (WP) and
39 80 Radibarrier.

41 81

43 82 **Materials and methods**

45 83 **Synthesis procedure of SR-Pb shield**

46 84 The thyroid shield was synthesized from silicon rubber (SR-RTV52) and lead type lead (II) acetate
47 85 trihydrate ($\text{Pb}(\text{CH}_3\text{COO})_2 \cdot 3\text{H}_2\text{O}$). There were many steps to synthesis the SR-Pb shield (Figure 1). The
48 86 first step was pouring SR and Pb to beaker glass with different percentage of Pb from 0 to 5 wt%.
49 87 Afterwards, it was then mixed for 30 minutes. To increase homogeneity of SR-Pb, sonication was
50 88 carried out with an ultrasonic bath. The next step was the vulcanization process to accelerate the drying
51 89 process of the thyroid shield. After the thyroid shield dries, it was ready to print the shield according to
52 90 the shape of the neck.




Figure 1. Synthesis procedure of SR-Pb thyroid shield.

Characterization of the SR-Pb shield

There are at least two important parameters of SR-Pb as an organ shield need to be characterized. Two characteristics of SR-Pb are effective atomic number (Z_{eff}) and elasticity. The Z_{eff} is most important parameters for tissue equivalence, radiation scattering, radiation absorption, and shielding effectiveness for X-ray radiation. The Z_{eff} of SR-Pb with different percentage of Pb from 0 to 5 wt% were calculated using Auto- Z_{eff} software version 1.7 [36]. The elasticity of the SR-Pb is also important due to its placement in irregular shape of the neck surface. For quantitative analysis, the elasticity of SR-Pb thyroid shield was measured by the value of the Young modulus and strain. The Young modulus is a measure of the stiffness of an elastic material, and the strain is the degree of change in the length of material for a given force.

Dose measurement

The dose received by thyroid with and without the SR-Pb thyroid shield was measured using Radiophoto-luminescence (RPL) glass detectors type GD-352M (Chiyoda Technol Corporation, Japan). The RPL detectors had a sensitivity range from 10 μGy to 10 Gy. Three RPLs were placed on the surface of the neck anthropomorphic phantom, as shown in Figure 2(a). The SR-Pb was shown in Figure 2(b). The SR-Pb shield was compared with Tungsten Paper (WP) (Toppan Printing and Kyoto University, Japan) (Figures 2(c)) and Radibarrier (Shin Etsu Chemical, Japan) (Figures 2(d)). The WP and Radibarrier have a thickness of 10 mm.

There were many steps in dose measurement using RPLs. After annealing at a temperature of 400° C to remove the previous dose stored, the initial dose value before irradiation is read to determine the background dose. Following the irradiation process, the RPLs were pre-heated at 80° C and read using the reader of Dose Ace type FDG-1000 (Chiyoda Technol Corporation, Japan). The scanning parameters were tabulated in Table 1. Each examination was repeated three times to verify the effect of the shield in reducing organ dose.




Figure 2. Placement of RPLs and thyroid shields. (a) 3 RPLs were placed on the surface of the neck phantom to measure doses received by the thyroid, (b) phantom with the SR-Pb thyroid shield, (c) phantom with Tungsten Paper (WP) sheet, and (d) phantom with the Radibarrier.

118
119

Table 1. The scanning parameters

Tube voltage	120 kVp
Tube current	150 mA
Time rotation	0.75 sec/rot
Slice thickness	5 mm
Field of view (FOV)	320 mm
Scan type	Helical
Pitch	1.375

120

121 Image quality evaluation

122 The image quality with and without thyroid shield was evaluated and compared. Image quality
123 evaluation is based on the consistency of HU values. Larger HU values compared with the image
124 without the thyroid shield were indicative of the presence of artifact in the image. For quantitative
125 analysis, artifact in the image was evaluated with four circular region of interests (ROIs) at areas of the
126 anterior (i.e. at the area of the thyroid), lateral soft tissue (i.e. right and left side) and at the posterior of
127 the neck. The size of each ROI was 112.14 mm². Locations of the ROIs in the image are shown in
128 Figure 3. For a detailed evaluation of image quality, image subtraction between images using a thyroid
129 shield and without it was performed.




Figure 3. Locations of the ROIs to calculate HU values. (a) Without thyroid shield, and (b) With SR-Pb thyroid shield.


130

131 Results

132 Characteristics of the SR-Pb shield


133 Figure 4 shows the Z_{eff} of the SR-Pb as a function of photon energy for various Pb percentage from 0
134 up to 5 wt%. The Z_{eff} values were constant in the intermedium energy region (0.5-5 MeV) and in the
135 very high energy (>100 MeV). A variation was observed in the lower energy (0.01-0.1 MeV) and in the

136 the high energy regions (5-100 MeV). It is found that the Z_{eff} values increased with an increase in Pb
 137 content in the SR-Pb as predicted.



138
 139 **Figure 4.** The Z_{eff} of the SR-Pb as a function of photon energy for various Pb percentage. (a) SR-Pb 0
 140 wt%, (b) SR-Pb 1 wt%, (c) SR-Pb 2 wt%, (d) SR-Pb 3 wt%, (e) SR-Pb 4 wt%, and (f) SR-Pb 5 wt%


141
 142 Figure 5 shows that the addition of Pb percentage caused an increase of Young modulus and a decrease
 143 of strain value. This happens because the level of deformation of the chain of SR molecules is limited
 144 by Pb and leads to increased stiffness and decreased change in the length of a material [37-39]. The
 145 thyroid shield with Pb 5 wt% has a value of the Young modulus and strain of 55.96 Pa and 62%,
 146 respectively. These values indicate that it still has sufficient elasticity to cover a non-flat organ such as
 147 the neck surface. Figure 2(b) shows visually the elasticity of the SR-Pb thyroid shields so that its
 148 placement in the throid area is very easy. This differs from Tungsten paper (WP) (Figures 2(c)) and the
 149 Radibarrier (Figures 2(d)), which do not have good elasticity and require tape to locate them in position
 150 on the thyroid area.



151
 152 **Figure 5.** Yong modulus and strain of the SR-Pb thyroid shield for
 various Pb percentage from 0 up to 5 wt%.

153 **Effect of thyroid shields on the dose reduction**

154 The superficial dose at the thyroid during CT examination of the neck using SR-Pb thyroid shields with
 155 a Pb content from 0 to 5 wt%, and its comparison with the WP and the Radibarrier thyroid shields, can
 156 be seen in Figure 6. The dose without thyroid shield 69.855 ± 0.8 mGy, and the dose reductions with
 157 the SR-Pb thyroid shields with variation of Pb percentage of 0, 1, 2, 3, 4 and 5 wt% are 12%, 18%,
 158 19%, 20%, 22% and 34%, respectively. It also shows that the Radibarrier has the greatest ability to
 159 reduce the dose to the thyroid, compared with SR-Pb and WP thyroid shields.



160 **Figure 6.** Thyroid dose in the CT examination of the neck, with and without thyroid shields.

161 **Effect of thyroid shield on the image quality**

162 Neck images with and without thyroid shields are shown in Figure 7. The resulting images using the
 163 SR-Pb thyroid shield do not reveal any artifacts in the thyroid (anterior area), lateral areas and posterior
 164 area, while the WP shield causes significant artifact in the anterior area, and minor artifact in the lateral
 165 and posterior areas. The Radibarrier provides severe artifact in all areas of the image (anterior, posterior
 166 and lateral).

167 The artifacts in the resulting image can be identified by increased HU values and its standard deviations
 168 in the anterior, lateral and posterior regions, tabulated in Table 2. The HU values of the SR-Pb increased
 169 slightly compared to those without the thyroid shield (8.8%), while the HU values in the anterior
 170 (thyroid area) of the WP and the Radibarrier increase significantly by up to 77.0% and 552.7%,
 171 respectively. Image quality using the SR-Pb shield was maintained, as evidenced by the SD values
 172 being similar to without the thyroid shield. WP and Radibarrier have higher difference SD values when
 173 compared with the image without a shield.




Figure 7. The resulting image of neck on the phantom with and without thyroid shield. (a) Without thyroid shield, (b) SR-Pb 0 wt%, (c) SR-Pb 1 wt%, (d) SR-Pb 2 wt%, (e) SR-Pb 3 wt%, (f) SR-Pb 4 wt%, (g) SR-Pb 5 wt%, (h) WP, and (i) Radibarrier. Window-width (W) is 350 and window-level (L) is 60.

174
175
176

Table 2. HU values and standard deviation of various thyroid shields in four ROI locations.

Thyroid shield	Area (mm ²)	Lateral							
		Anterior		Right side				Posterior	
		HU	SD	HU	SD	HU	SD	HU	SD
Without	112.14	119.25	2.41	125.30	2.19	125.30	2.29	126.39	3.62
SR-Pb 0 wt%	112.14	120.04	2.60	126.26	1.88	119.16	2.59	126.51	4.03
SR-Pb 1 wt%	112.14	125.37	2.83	121.21	2.27	123.74	2.37	126.73	4.35
SR-Pb 2 wt%	112.14	123.73	3.12	127.71	2.07	120.97	2.85	126.25	3.91
SR-Pb 3 wt%	112.14	126.69	3.32	128.98	2.45	120.67	2.69	127.59	3.87
SR-Pb 4 wt%	112.14	128.84	3.20	129.15	2.30	120.71	2.64	127.71	3.60
SR-Pb 5 wt%	112.14	129.78	4.17	128.62	2.33	122.58	2.69	127.74	3.95
WP	112.14	211.05	19.42	143.98	3.09	133.34	3.39	135.30	3.64
Radibarrier	112.14	778.39	148.69	215.36	8.29	296.51	18.15	202.38	6.67

1
2
3 177 To ensure that the SR-Pb thyroid shield does not cause artifact in the resulting image, a detailed
4 178 evaluation using subtraction image between the image with and without thyroid shield was conducted.
5 179 The subtraction images are shown in Figure 8. This shows that using the SR-Pb with various percentages
6 180 of Pb from 0-5 wt%, the resulting image can be maintained for diagnostic purposes because there is
7 181 only a small artifact. Conversely, WP and the Radibarrier cannot be used for diagnostic purposes
8 182 because both cause severe artifact in the image.

183




Figure 8. Images of the image subtraction between with and without thyroid shields. (a) SR-Pb 0 wt%, (b) SR-Pb 1 wt%, (c) SR-Pb 2 wt%, (d) SR-Pb 3 wt%, (e) SR-Pb 4 wt%, (f) SR-Pb 5 wt%, (g) WP, and (h) Radibarrier. Window-width (W) is 600 and window-level (L) is 16.

184

185 Discussion

186 One straightforward method to reduce the surface dose on CT examination, including the dose on the
187 surface of the thyroid, is to use an organ shield. The main problem with the use of organ shields is the
188 appearance of artifacts in the image that can interfere with diagnosis [24-28]. In the hope of avoiding
189 artifact, a previous study developed a new material for an organ shield from SR material mixed with
190 variation percentages of Pb from 0 to 5 wt% [35]. Increasing the Pb content leads to an increase in the
191 dose reduction of the surface of eye lens. The addition of Pb 5 wt% in the SR-Pb shield can reduce the
192 eye dose up to 50% [35]. Dose reduction in the thyroid (34%) is smaller than in the eye lens likely
193 because the SR-Pb shield protects from many sides (i.e. above, right and left sides), while in the thyroid,
194 the SR-Pb shield protects radiation only from above. A better design of the thyroid shield may be able
195 increase dose reduction.

196 The use of a SR-Pb shield has only a slight impact on the resulting image. The quality of the image is
197 maintained for diagnostic proposes, even though the SR-Pb thyroid shield is in contact with the surface
198 of the organ, i.e. thyroid or eye lens.

199 The WP and Radibarrier shields reduce thyroid dose by more than the SR-Pb shield, viz. 36% and 67%,
200 respectively. However the resulting images suffer severe artifacts which can lead to mis-diagnosis in
201 the anterior, posterior and lateral areas. Radiation absorption depends on the atomic number (Z) of
202 material, with higher atomic number material having a greater ability to absorb radiation [33, 39].
203 Tungsten (W) has a Z value of 71 and its percentage in the WP shield is about 80%, while the
204 Radibarrier has a lead equivalent of 1.1 mm, where lead has a Z value of 82. Unfortunately both cause

60

205 significant artifacts and noise in the resulting image. In the SR-Pb shield, the Pb content is low (0-5
206 wt%) so that the Pb is distributed uniformly in the SR-Pb sheet, hence artifact can be avoided.

207 The protection of thyroid gland is crucial because the thyroid is one of the most radiosensitive
208 organs and is vulnerable to stochastic effects such as cancer. Based on our results, the SR-Pb
209 thyroid shield may be recommended in the CT examination of the neck replacing the bismuth
210 thyroid shield. Even though the reduction dose of SR-Pb is smaller than bismuth shield, it is
211 preferred because artifact is almost non-existent in the SR-Pb.

212 The SR-Pb thyroid shield is non-toxic, so it is safe to use. Another advantage is its elasticity,
213 so it is easy to use, easily positioned and removed, and has sufficient flexibility to cover an
214 organ. It is not time-consuming to use, and therefore dose reduction does not prolong
215 examination time. It is light –weight so that patients will feel comfortable when using it. It may
216 also reduce the patient’s anxiety about the impact of radiation, because the patient is aware that
217 he/she is protected.

218 The limitations of this study are that validation was only performed on a phantom, with a single
219 size representing an average-size patient not pediatric or obese patient, and the image quality
220 was evaluated quantitatively without observation by expert radiologists. A further study on SR-
221 Pb thyroid shield with a possible combination of the ATCM might be more challenging. In the
222 CT examination equipped with ATCM, the SR-Pb placement before the scout might change
223 the current in the ATCM, so that in clinical applications, SR-Pb should be placed after scout
224 image is obtained.

225

226 **Conclusions**

227 The thyroid shield made from SR-Pb has been successfully synthesized and validated. The use of the
228 SR-Pb thyroid shield can reduce thyroid dose. The reduction in dose increases with the increasing
229 percentage of Pb. In SR-Pb 5 wt% the decreasing in dose was 34% compared with having no thyroid
230 shield. The resulting image is of high quality without artifact even at higher percentage of Pb so that
231 it can be used without mis-diagnosis. The SR-Pb thyroid shield is very practical because it can be placed
232 directly above the surface of the thyroid, and is sufficiently flexible to cover the thyroid. Hence, we
233 recommend its adoption for clinical CT neck examinations.

234

235 **Acknowledgment**

236 The authors would like to thank the Ministry of research, Technology and Higher Education of the
237 Republic of Indonesia for funding this research in 2019.

238

239 **References**

- 240 [1] Anam C, Fujibuchi T, Budi WS, Haryanto F and Dougherty G 2018 An algorithm for automated
241 modulation transfer function measurement using an edge of a PMMA phantom: Impact of field
242 of view on spatial resolution of CT images *J. Appl. Clin. Med. Phys.* **19** 244-252
- 243 [2] Lewis MA and Edyvean S 2005 Patient dose reduction in CT *Br. J. Radiol.* **78** 880–883
- 244 [3] Artells MS and Veldkamp WJH 2006 Quantitative assessment of selective in-plane shielding of
245 tissues in computed tomography through evaluation of absorbed dose and image quality *Eur. J.*
246 *Radiol.* **16** 2334–2340
- 247 [4] Brenner DJ and Hall EJ 2007 Computed tomography — an increasing source of radiation
248 exposure *N. Engl. J. Med.* **357** 2277–2284
- 249 [5] Goldman LW 2007 Principles of CT: Radiation dose and image quality *Nucl. Med. Technol.* **35**
250 213–225
- 251 [6] Catuzzo P, Aimonetto S, Fanelli G, et al. 2010 Dose reduction in multislice CT by means of
252 bismuth shields: results of in vivo measurements and computed evaluation *Radiol. Med.* **115**

- 1
2
3 253 152–169
- 4 254 [7] Gunn ML, Kanal KM, Kolokythas O and Anzai Y 2009 Radiation dose to the thyroid gland and
5 255 breast from multidetector computed tomography of the cervical spine: does bismuth shielding
6 256 with and without a cervical collar reduce dose? *J. Comput. Assist. Tomogr.* **33** 987–990
- 7 257 [8] Chang KH, Lee W, Choo DM, Lee CS and Kim Y 2009 Dose reduction in CT using bismuth
8 258 shielding: Measurements and Monte Carlo simulations *Radiat. Prot. Dosimetry.* **138** 382–388
- 9 259 [9] Brenner ADJ 2010 Slowing the increase in the population dose resulting from CT scans slowing
10 260 the increase in the population dose resulting from CT scans *Radiat. Res. Soc.* **174** 809–815
- 11 261 [10] Antypas EJ, Sokhandon F, Farah M, et al. 2011 A comprehensive approach to CT radiation dose
12 262 reduction: one institution's experience *Am. J. Roentgenol.* **197** 935–940
- 13 263 [11] Alkhorayef M, Babikir E, Alrushoud A, Al-mohammed H and Sulieman A 2017 Patient radiation
14 264 biological risk in computed tomography angiography procedure *SAUDI J. Biol. Sci.* **24** 235–240
- 15 265 [12] Alkhorayef M, Sulieman M, Alonazi B, Alnaaimi M, Alduaij M and Bradley D 2019 Estimation
16 266 of radiation-induced cataract and cancer risks during routine CT head procedures *Radiat. Phys.*
17 267 *Chem.* **155** 65–68
- 18 268 [13] Kim KP, Berrington de González A, Pearce MS, et al. 2012 Development of a database of organ
19 269 doses for paediatric and young adult CT scans in the United Kingdom *Radiat. Prot. Dosimetry.*
20 270 **150** 415–426
- 21 271 [14] Hamada N and Fujimichi Y 2014 Classification of radiation effects for dose limitation purposes:
22 272 history, current situation and future prospects *Radiat. Res.* **55** 629–640
- 23 273 [15] Chen JX, Kachniarz B, Gilani S and Shin JJ. Risk of malignancy associated with head and neck
24 274 CT in children: a systematic review *Otolaryngol. Head. Neck. Surg.* **151** 554–566
- 25 275 [16] Akhlaghi P, Hakimabad HM and Motavalli LR 2013 An overview of exposure parameters, dose
26 276 measurements and strategies for dose reduction in pediatric CT examinations *Radioprotection* **49**
27 277 9–15
- 28 278 [17] Alonso TC, Mourão AP, Santana PC and Teógenes A 2016 Assessment of breast absorbed doses
29 279 during thoracic computed tomography scan to evaluate the effectiveness of bismuth shielding
30 280 *Appl. Radiat. Isot.* **117** 55–57
- 31 281 [18] Hoang JK, Yoshizumi TT, Choudhury KR, et al. 2012 Organ-based dose current modulation and
32 282 thyroid shields: techniques of radiation dose reduction for neck CT *Am. J. Roentgenol.* **198** 1132–
33 283 1138
- 34 284 [19] Mendes M, Costa F, Figueira C, Madeira P, Teles P and Vaz P 2015 Assessment of patient dose
35 285 reduction by Bismuth shielding in CT using measurements, GEANT4 and MCNPX simulations
36 286 *Radiat. Prot. Dosimetry.* **165** 175–181
- 37 287 [20] Lawrence S and Seeram E 2017 The current use and effectiveness of bismuth shielding in
38 288 computed tomography: a systematic review *Radiol. Open. J.* **2** 7–16
- 39 289 [21] Russell MT, Fink JR, Rebeles F, Kanal K and Ramos M 2008 Balancing radiation dose and image
40 290 quality: clinical applications of neck volume CT *Am. J. Neuroradiol.* **29** 727–731
- 41 291 [22] Samei E 2014 Pros and cons of organ shielding for CT imaging *Pediatr. Radiol.* **44** 495–500
- 42 292 [23] Anam C, Budi WS, Adi K, et al. 2019 Assessment of patient dose and noise level of clinical CT
43 293 images: automated measurements *J. Radiol. Prot.* **39** 783–793
- 44 294 [24] Hohl C, Wildberger JE, Süß C, et al. 2009 Radiation dose reduction to breast and thyroid during
45 295 MDCT: effectiveness of an in-plane bismuth shield *Acta. Radiol.* **47** 562–567
- 46 296 [25] Gbelcová L, Nikodemová D and Horváthová M 2011 Dose reduction using bismuth shielding
47 297 during paediatric CT examinations in Slovakia *Radiat. Prot. Dosimetry* **147** 160–163
- 48 298 [26] Nikodemova D and Horva M 2011 Dose reduction using bismuth shielding during paediatric CT
49 299 examinations in slov *Radiat. Prot. Dosimetry.* **147** 160–163
- 50 300 [27] Lee YH, Park ET, Cho PK, et al. 2011 Comparative analysis of radiation dose and image quality
51 301 between thyroid shielding and unshielding during CT examination of the neck *Am. J. Roentgenol.*
52 302 **196** 611–615
- 53 303 [28] Inkoom S, Papadakis AE, Raissaki M, et al. 2017 Paediatric neck multidetector computed
54 304 tomography: the effect of bismuth shielding on thyroid dose and image quality *Radiat. Prot.*
55 305 *Dosimetry.* **173** 361–373
- 56 306 [29] Anam C, Haryanto F, Widita R, Arif I, Dougherty G and McLean D 2018 Volume computed
57 307 tomography dose index (CTDIvol) and size-specific dose estimate (SSDE) for tube current

- 1
2
3 308 modulation (TCM) in CT scanning *Int. J. Radiat. Res.* **16** 289-297
- 4 309 [30] Solomon JB, Li X and Samei E 2013 Relating noise to image quality indicators in CT
5 310 examinations with tube current modulation *Am. J. Roentgenol.* **200** 592–600
- 6 311 [31] Papadakis AE, Perisinakis K and Damilakis J 2014 Automatic exposure control in CT: the effect
7 312 of patient size, anatomical region and prescribed modulation strength on tube current and image
8 313 quality *Eur. J. Radiol.* **24** 2520–2531
- 9 314 [32] Leswick DA, Hunt MM, Webster ST and Fladeland DA 2008 Thyroid shields versus z-axis
10 315 automatic tube current modulation for dose reduction at neck CT *Radiology* **249** 572–580
- 11 316 [33] La LBT, Leong YK, Leatherday C, et al. 2016 X-ray protection, surface chemistry and rheology
12 317 of ball-milled submicron Gd₂O₃ aqueous suspension *Colloids and Surfaces A: Physicochemical
13 318 and Engineering Aspects* **501** 75–82
- 14 319 [34] Zhang J and Oates ME 2012 CT bismuth breast shielding: Is it time to make your own decision?
15 320 *J. Am. Coll. Radiol.* **9** 856–858
- 16 321 [35] Irdawati Y, Sutanto H, Anam C, Fujibuchi T, Zahroh F, Dougherty G 2019 Development of a
17 322 novel artifact-free eye shield based on silicon rubber-lead composition in the CT examination on
18 323 the head *J. Radiol. Prot.* **39** 991-1005
- 19 324 [36] Taylor ML, Smith RL, Dossing F and Franich RD 2012 Robust calculation of effective atomic
20 325 numbers: The Auto-Zeff software *Med. Phys.* **39** 1769-1778
- 21 326 [37] Araby S, Zhang L, Kuan HC, Dai JB, Majewski P and Ma J 2013 A novel approach to electrically
22 327 and thermally conductive elastomers using graphene *Polymer* **54** 3663–3670
- 23 328 [38] Kang H, Zuo K, Wang Z, Zhang L, Liu L and Guo B 2014 Using a green method to develop
24 329 graphene oxide/elastomers nanocomposites with combination of high barrier and mechanical
25 330 performance *Compos. Sci. Technol.* **92** 1–8
- 26 331 [39] Yang H, Yao X, Zheng Z, et al. 2018 Highly sensitive and stretchable graphene-silicone rubber
27 332 composites for strain sensing *Compos. Sci. Technol.* **167** 371–378
- 28 333 [40] Atashi P, Rahmani S, Ahadi B and Rahmati A 2018 Efficient, flexible and lead-free composite
29 334 based on room temperature vulcanizing silicone rubber/W/Bi₂O₃ for gamma ray shielding
30 335 application *J. Mater. Sci. Mater. Electron.* **29** 12306–12322

33 336
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subjek: Your submission to Biomed. Phys. Eng. Express: BPEX-101752



Biomedical Physics & Engineering Express <onbehalfof@manuscriptcentral.com>

kepada herisutanto, yulia.irdawati.2018, anam, ekohidayanto, zaenalarifin, fujibuch, Geoff.Dougherty, jwsono, bahruddii

Anda sedang melihat pesan terlampir. Email FISIKA UNDIP tidak dapat memverifikasikan keautentikan pe

Dear Dr Sutanto,

Re: "An artifact-free thyroid shield in CT examination: a phantom study" by Sutanto, Heri; Irdawati, Yulia; Anan
Article reference: BPEX-101752

Thank you for submitting your Paper, which will be considered for publication in Biomedical Physics & Enginee
manuscript.

As the submitting author, you can follow the progress of your article by checking your Author Centre after loggi
reports and send us your electronic files.

This journal makes manuscripts available to readers on the journal website within 24 hours of acceptance. Ple
journal's website before it is proof-read and formatted to our house style.

If you are planning any press activity for your article, or are currently engaging in an IP or patent application, y
manuscript immediately visible to readers, and have not ticked the opt-out box during submission, please let u

Please do not hesitate to contact us if we can be of assistance to you.

Yours sincerely

On behalf of the IOP peer-review team:

Jade Holt - Managing Editor

Maddy Cumbes - Associate Editor

Blythe Rowley & Jo Bewley - Editorial Assistants

Want to find out what is happening to your submission right now? Track your article here: <https://publishingsup>

bpex@iopublishing.org

Robert Jeraj - Editor-in-Chief

Lauren Carter - Publisher

IOP Publishing

Temple Circus, Temple Way, Bristol, BS1 6HG, UK

www.iopscience.org/bpex

Referee: 1

COMMENTS TO THE AUTHOR(S)

This study investigated the SR-Pb shield in terms of dose reduction and image quality with comparison of two other shields. The author concluded that SR-Pb shield has a good dose reduction performance with a much less affect in image quality than the other two shields.

Overall the manuscript is well organized, while the writing of English needs improvement. The author needs to proof read the manuscript carefully before the next round of review.

Introduction:

1. Page2, line 9, "the reduction thyroid shield is in range from 23% to 35%." This is unclear. It should clearly indicate "the reduction of dose by thyroid shield ..."
2. Page2 line 20, "because ATCM depending on ..." should be "because ATCM depends on..."

Materials and methods

3. The description of flexibility of SR-Pb and its comparison with other shields should be placed in a separate section. Now it is under "dose measurement" section, which is confusing.
4. The description about the elasticity study in result part should be moved to Method part.

Results

5. Fig 4 should use two different markers to differentiate the two datasets if the manuscript will be published in black and white.
6. Could the author provide the Young modulus for the other two shields as well just for reference?
7. Page 4, line 34, author need to cite the reference about " The Radibarrier has equivalently to lead 1.1 mm and its rate of x-ray blocking is about 99% "
8. The legend of Fig 6 should indicate the window and level for this fig.
9. The legend of Fig 7 also needs to specify the window and level. In addition, the window and level looks differently among the eight sub-figures. I suggest to keep the same window and level to all sub-figures.

Discussion

10. Could the author estimate the effective Z and equivalent lead thickness of the SR-Pb proposed in this study?
11. Page 8, line 18, "The optimization of between dose reduction and image quality when using thyroid shield. " is not a complete sentence.
12. Page 8, line 27 "... because the artifact is almost not exist in the SR-Pb" should be "does not exist"

AUTHORS GENERAL RESPONSES:

Thank you very much for your valuable comments and suggestions. We have revised the manuscript accordingly and have carefully proof-read the manuscript.

SPECIFIC RESPONSES:

1. We have changed the statement "the reduction thyroid shield is in range from 23% to 35%" to "the reduction of dose by thyroid shield is in range from 23% to 35%". Please see the revised manuscript, page 2, line 49.
 2. We have changed "because ATCM depending on ..." to "because ATCM depends on..." as suggested. Please see the revised manuscript, page 2, line 61.
 3. We have made a new section in the Method, i.e., "Characterization of the SR-Pb Shield". This section explains the elasticity and the effective atomic number (Z_{eff}) of the SR-Pb section. Please see the revised manuscript, page 3, lines 41-100.
 4. We have moved the description about the elasticity of the SR-Pb in Result part to a new section in the Method. Please see also the 4th point. Please see the revised manuscript, page 3, lines 41-100.
 5. We have used two different markers to differentiate the two datasets in Fig 5. Note: We have added a new figure (Figure 4), therefore the Figure 4 becomes Figure 5. Please see the revised manuscript, page 5, lines 152.
 6. Thank you very much for your useful suggestion. However, it is difficult for us to do. We measure Young modulus in one laboratory in Indonesia, while the two shields (WP and Radibarrier) are in Japan.
 7. We have erased this statement due to it does not support our finding. Please see the revised manuscript.
 8. We have added an information of the window-width (W) and window-level (L) in the figure. All images have the same W and L. The W is 350 and L is 60. Please see the new Figure 7 and its caption in the revised manuscript, page 7, lines 175-177.
 9. We have added an information of the window-width (W) and window-level (L) in the figure. All images have the same W and L. The W is 600 and L is 16. Please see the new Fig 8 and its caption in the revised manuscript, page 8, lines 184-185.
 10. We have calculated the Z_{eff} of SR-Pb and we have included in the particular section in Method and Results. We have also added one figure on Z_{eff} of SR-Pb. Please see the revised manuscript, page 3, lines 41-100 and page 4 line 133 to page 4 line 141.
 11. We have re-phrased the paragraph accordingly. "Tungsten (W) has a Z value of 71 and its percentage in the WP shield is about 80%, while the Radibarrier has a lead equivalent of 1.1 mm, where the lead has Z value of 82. Unfortunately, both cause significant artifacts and noise in the resulting image. In the SR-Pb shield, the Pb content is (0-5 wt%) so that the Pb is distributed uniformly in the SR-Pb sheet, hence artifact can be avoided." Please see the revised manuscript, page 8 line 205 to page 9 line 208.
 12. We have re-phrased the paragraph accordingly. "The protection of thyroid gland is crucial because the thyroid is one of the most radiosensitive organs and is vulnerable to stochastic effects such as cancer. Based on our results, the SR-Pb thyroid shield may be recommended in the CT examination of the neck replacing the bismuth thyroid shield. Even though the reduction dose of SR-Pb is smaller than bismuth shield, it is preferred because artifact is almost non-existent in the SR-Pb". Please see the revised manuscript, page 9 lines 209-213.
-

Decision Letter (BPEX-101752)

From: bpex@iopublishing.org

To: herisutanto@fisika.undip.ac.id

CC: herisutanto@fisika.undip.ac.id, yulia.irdawati.2018@fisika.fsm.undip.ac.id, anam@fisika.undip.ac.id, ekohidayanto@fisika.undip.ac.id, zaenalarifin@fisika.undip.ac.id, fujibuch@hs.med.kyushu-u.ac.jp, Geoff.Dougherty@csuci.edu, jwsono@metal.ui.ac.id, bahrudin@lecturer.unri.ac.id

Subject: Our initial decision on your article: BPEX-101752

Body: Dear Dr Sutanto,

Re: "An artifact-free thyroid shield in CT examination: a phantom study" by Sutanto, Heri; Irdawati, Yulia; Anam, Choirul; Hidayanto, Eko; Arifin, Zaenal; Fujibuchi, Toshio; Dougherty, Geoff; Soedarsono, Johni; Bahrudin, Bahrudin
Article reference: BPEX-101752

We have now received the referee report(s) on your Paper, which is being considered by Biomedical Physics & Engineering Express.

The referee(s) have recommended that you make some amendments to your article. The referee report(s) can be found below and/or attached to this message. You can also access the reports at your Author Centre, at <https://mc04.manuscriptcentral.com/bpex-iop>

Please consider the referee comments and amend your article according to the recommendations. You should then send us a clean final version of your manuscript. Please also send (as separate files) point-by-point replies to the referee comments and either a list of changes you have made or an additional copy of your manuscript with the changes highlighted (for further information visit <https://publishingsupport.iopscience.iop.org/questions/how-to-prepare-your-revised-article/>). This will aid our referees in reviewing your revised article. Please upload the final version and electronic source files to your Author Centre by 21-Jan-2020.

If we do not receive your article by this date, it may be treated as a new submission, so please let us know if you will need more time.

We look forward to hearing from you soon.

Yours sincerely

Maddy Cumbes

On behalf of the IOP peer-review team:
Jade Holt - Managing Editor
Maddy Cumbes - Associate Editor
Blythe Rowley & Jo Bewley - Editorial Assistants

Want to find out what is happening to your submission right now? Track your article here:
https://publishingsupport.iopscience.iop.org/track-my-article/?utm_source=Track%20my%20article&utm_medium=Email

bpex@iopublishing.org

Robert Jeraj - Editor-in-Chief
Lauren Carter - Publisher

IOP Publishing
Temple Circus, Temple Way, Bristol, BS1 6HG, UK

www.iopscience.org/bpex

REFEREE REPORT(S):
Referee: 1

COMMENTS TO THE AUTHOR(S)

This study investigated the SR-Pb shield in terms of dose reduction and image quality with comparison of two other shields. The author concluded that SR-Pb shield has a good dose reduction performance with a much less affect in image quality than the other two shields.

Overall the manuscript is well organized, while the writing of English needs improvement. The author needs to proof read the manuscript carefully before the next round of review.

Introduction:

1. Page2, line 9, "the reduction thyroid shield is in range from 23% to 35%." This is unclear. It should clearly indicate "the reduction of dose by thyroid shield ..."
2. Page2 line 20, "because ATCM depending on ..." should be "because ATCM depends on..."

Materials and methods

3. The description of flexibility of SR-Pb and its comparison with other shields should be placed in a separate section. Now it is under "dose measurement" section, which is confusing.
4. The description about the elasticity study in result part should be moved to Method part.

Results


5. Fig 4 should use two different markers to differentiate the two datasets if the manuscript will be published in black and white.
6. Could the author provide the Young modulus for the other two shields as well just for reference?
7. Page 4, line 34, author need to cite the reference about " The Radibarrier has equivalently to lead 1.1 mm and its rate of x-ray blocking is about 99%"
8. The legend of Fig 6 should indicate the window and level for this fig.
9. The legend of Fig 7 also needs to specify the window and level. In addition, the window and level looks differently among the eight sub-figures. I suggest to keep the same window and level to all sub-figures.

Discussion

10. Could the author estimate the effective Z and equivalent lead thickness of the SR-Pb proposed in this study?
11. Page 8, line 18, "The optimization of between dose reduction and image quality when using thyroid shield. " is not a complete sentence.
12. Page 8, line 27 "... because the artifact is almost not exist in the SR-Pb" should be "does not exist"

Letter reference: DSMo01

Date Sent: 07-Jan-2020

 Close Window

Decision Letter (BPEX-101752)

From: bpex@iopublishing.org

To: herisutanto@fisika.undip.ac.id

CC: herisutanto@fisika.undip.ac.id, yulia.irdawati.2018@fisika.fsm.undip.ac.id, anam@fisika.undip.ac.id, ekohidayanto@fisika.undip.ac.id, zaenalarifin@fisika.undip.ac.id, fujibuch@hs.med.kyushu-u.ac.jp, Geoff.Dougherty@csuci.edu, jwsono@metal.ui.ac.id, bahrudin@lecturer.unri.ac.id

Subject: Our initial decision on your article: BPEX-101752

Body: Dear Dr Sutanto,

Re: "An artifact-free thyroid shield in CT examination: a phantom study" by Sutanto, Heri; Irdawati, Yulia; Anam, Choirul; Hidayanto, Eko; Arifin, Zaenal; Fujibuchi, Toshioh; Dougherty, Geoff; Soedarsono, Johni; Bahrudin, Bahrudin
Article reference: BPEX-101752

We have now received the referee report(s) on your Paper, which is being considered by Biomedical Physics & Engineering Express.

The referee(s) have recommended that you make some amendments to your article. The referee report(s) can be found below and/or attached to this message. You can also access the reports at your Author Centre, at <https://mc04.manuscriptcentral.com/bpex-iop>

Please consider the referee comments and amend your article according to the recommendations. You should then send us a clean final version of your manuscript. Please also send (as separate files) point-by-point replies to the referee comments and either a list of changes you have made or an additional copy of your manuscript with the changes highlighted (for further information visit <https://publishingsupport.iopscience.iop.org/questions/how-to-prepare-your-revised-article/>). This will aid our referees in reviewing your revised article. Please upload the final version and electronic source files to your Author Centre by 21-Jan-2020.

If we do not receive your article by this date, it may be treated as a new submission, so please let us know if you will need more time.

We look forward to hearing from you soon.

Yours sincerely

Maddy Cumbes

On behalf of the IOP peer-review team:
Jade Holt - Managing Editor
Maddy Cumbes - Associate Editor
Blythe Rowley & Jo Bewley - Editorial Assistants

Want to find out what is happening to your submission right now? Track your article here:
https://publishingsupport.iopscience.iop.org/track-my-article/?utm_source=Track%20my%20article&utm_medium=Email

bpex@iopublishing.org

Robert Jeraj - Editor-in-Chief
Lauren Carter - Publisher

IOP Publishing
Temple Circus, Temple Way, Bristol, BS1 6HG, UK

www.iopscience.org/bpex

REFEREE REPORT(S):
Referee: 1

COMMENTS TO THE AUTHOR(S)

This study investigated the SR-Pb shield in terms of dose reduction and image quality with comparison of two other shields. The author concluded that SR-Pb shield has a good dose reduction performance with a much less affect in image quality than the other two shields.

Overall the manuscript is well organized, while the writing of English needs improvement. The author needs to proof read the manuscript carefully before the next round of review.

Introduction:

1. Page2, line 9, "the reduction thyroid shield is in range from 23% to 35%." This is unclear. It should clearly indicate "the reduction of dose by thyroid shield ..."
2. Page2 line 20, "because ATCM depending on ..." should be "because ATCM depends on..."

Materials and methods

3. The description of flexibility of SR-Pb and its comparison with other shields should be placed in a separate section. Now it is under "dose measurement" section, which is confusing.
4. The description about the elasticity study in result part should be moved to Method part.

Results


5. Fig 4 should use two different markers to differentiate the two datasets if the manuscript will be published in black and white.
6. Could the author provide the Young modulus for the other two shields as well just for reference?
7. Page 4, line 34, author need to cite the reference about " The Radibarrier has equivalently to lead 1.1 mm and its rate of x-ray blocking is about 99%"
8. The legend of Fig 6 should indicate the window and level for this fig.
9. The legend of Fig 7 also needs to specify the window and level. In addition, the window and level looks differently among the eight sub-figures. I suggest to keep the same window and level to all sub-figures.

Discussion

10. Could the author estimate the effective Z and equivalent lead thickness of the SR-Pb proposed in this study?
11. Page 8, line 18, "The optimization of between dose reduction and image quality when using thyroid shield. " is not a complete sentence.
12. Page 8, line 27 "... because the artifact is almost not exist in the SR-Pb" should be "does not exist"

Letter reference: DSMo01

Date Sent: 07-Jan-2020

 Close Window

Decision Letter (BPEX-101752.R1)

From: bpex@iopublishing.org

To: herisutanto@live.undip.ac.id, yulia.irdawati.2018@fisika.fsm.undip.ac.id, anam@fisika.fsm.undip.ac.id, fujibuch@hs.med.kyushu-u.ac.jp, Geoff.Dougherty@csuci.edu, ekohidayanto@fisika.undip.ac.id, zaenalarifin@fisika.undip.ac.id, jwsono@metal.ui.ac.id, bahrudin@lecturer.unri.ac.id

CC:

Subject: Your Paper has now been accepted for publication

Body: Dear Dr Sutanto,

Re: "An artifact-free thyroid shield in CT examination: a phantom study" by Sutanto, Heri; Irdawati, Yulia; Anam, Choirul; Fujibuchi, Toshioh; Dougherty, Geoff; Hidayanto, Eko; Arifin, Zaenal; Soedarsono, Johni; ., Bahrudin
Article reference: BPEX-101752.R1

We are pleased to tell you that we have now formally accepted your Paper. We have everything we need to proceed to publish your Paper in Biomedical Physics & Engineering Express. Unless you opted out during the submission process, the accepted manuscript (<http://iopscience.iop.org/page/acceptedmanuscripts>) will be made available online within the next 24 hours. You will receive an email to confirm this, which will also include the permanent DOI to use to cite your work.

If you have chosen to publish your Paper on an open access basis, or if there are other charges related to your Paper you will receive an email with details on how to pay within the next few days.

We will contact you again soon when proofs of your article are ready for final approval. Please return your article proofs by the date given to enable us to publish the final version of record as soon as possible.

All articles published by IOP Publishing are available online to readers at <http://iopscience.org/>. For more information, please contact our Customer Services department at customerservices@iopublishing.org. For advice on complying with US funder requirements, please go to <http://iopscience.iop.org/info/page/chorus>.

Thank you for choosing to publish in Biomedical Physics & Engineering Express. We look forward to publishing your Paper.

Yours sincerely

Blythe Rowley

On behalf of the IOP peer-review team:
Jade Holt - Managing Editor
Maddy Cumbes - Associate Editor
Blythe Rowley & Jo Bewley - Editorial Assistants

Want to find out what is happening to your submission right now? Track your article here:
https://publishingsupport.iopscience.iop.org/track-my-article/?utm_source=Track%20my%20article&utm_medium=Email

bpex@iopublishing.org

Robert Jeraj - Editor-in-Chief
Lauren Carter - Publisher

IOP Publishing
Temple Circus, Temple Way, Bristol, BS1 6HG, UK

www.iopscience.org/bpex

Letter reference: DRWA03

Date Sent: 22-Jan-2020

Follow [the instructions](#) before completing and submitting the agreement. Click the "Save as Draft" button to save it and return to it later, or the "Submit" button to submit it to the journal. Please email permissions@iopublishing.org with any questions, quoting the Article reference number.

Copyright and Publication Agreement

IOP Publishing Limited ("IOP") agrees to publish:

Manuscript Title: An artifact-free thyroid shield in CT examination: a phantom study (the "Article") written by

Names of all authors: Sutanto, Heri; Irdawati, Yulia; Anam, Choirul; Hidayanto, Eko; Arifin, Zaenal; Fujibuchi, Toshioh; Dougherty, Geoff; Soedarsono, Johni; Bahruddin, Bahruddin ("the Named Authors") in the following journal Biomedical Physics & Engineering Express ("the Journal")

If the Named Authors do NOT own the copyright in the Article, please write the full name of the organization/institution/company which owns the copyright here (see instructions [here](#)).

THIS BOX SHOULD BE LEFT BLANK IF THE NAMED AUTHORS OWN THE COPYRIGHT
(the "Copyright Owner")

IOP Ref: BPEX-101752.R1

Part 1: Publication on a Subscription Basis

1 In consideration for acceptance and publication of the Article, the Named Authors and/or the Copyright Owner assign, where necessary by present assignment of future copyright, to IOP with full title guarantee the entire copyright in all original material published as part of the Article (which expression includes but is not limited to the text, abstract, tables, figures and graphs, related corrigenda or "comments" and multimedia content but excludes any other item referred to as supplementary material and/or any video abstract) throughout the world for the full term of copyright (including any extensions or renewals thereof) for all media and formats, whether known or unknown. Such assignment shall be effective only if the Article (or any resubmission of the Article) is accepted for publication. For the avoidance of doubt, copyright does not subsist in any fundamental data underlying the Article and nothing in this agreement is intended to limit access to or use of such data.

2 The Named Authors' rights.

2.1 IOP grants the Named Authors the rights specified in <https://publishingsupport.iopscience.iop.org/author-rights-policies/>.

2.2 In summary, the Named Authors may only include the Final Published Version of the Article in certain prescribed circumstances. The Accepted Manuscript of the Article may be included in more instances, provided in all cases use is in accordance with the Author Rights set out at <https://publishingsupport.iopscience.iop.org/author-rights-policies/> on the date of submission of the

agreement.

Part 2: Publication on a Gold Open Access Basis

1.1 In consideration for acceptance and publication of the Article, the Named Authors of the Article and/or the Copyright Owner grant IOP a royalty-free, non-exclusive, freely transferrable, worldwide, perpetual licence for the full term of copyright (including any extensions or renewals) for all media and formats, whether known or unknown, to do in relation to the Article (which expression includes the text, abstract, tables, figures and graphs, related corrigenda or "comments" and multimedia content but excludes any other item referred to as supplementary material and/or any video abstract) all acts restricted by copyright worldwide. Such licence shall be effective only if the Article (or any resubmission of it) is accepted for publication. Copyright does not subsist in any fundamental data underlying the Article and nothing in the agreement is intended to limit access to or use of such data.

1.2 Each of the Named Authors and, where relevant, the Copyright Owner consents to the publication of the Article under [the Creative Commons Attribution 4.0 International licence \(CC BY 4.0\)](#) or any successor to that licence.

Part 3: General (Applicable to both Subscription and Gold Open Access Articles)

1.1 If the Article, or any part of it, is protected by Crown copyright, in consideration for acceptance and publication of the Article, the relevant Named Authors and/or the originating department or agency grant IOP a non-exclusive royalty-free worldwide freely-transferrable perpetual licence for the full term of copyright (including any extensions or renewals) for all media and formats, whether known or unknown, to do in relation to the Article all acts restricted by copyright worldwide including the right of action under section 101A of the Copyright Designs and Patents Act 1988.

1.2 If any of the Named Authors are employees of the US Government, please refer to [the US Government policy](#).

1.3 In consideration for acceptance and publication of the Article, the Named Authors and/or the Copyright Owner grant IOP a royalty-free non-exclusive worldwide freely transferrable worldwide perpetual licence for the full term of copyright (including any extensions or renewals) for all media and formats, whether known or unknown, to do in relation to any supplementary material not deemed to be part of the Article, and/or any video abstract, all acts restricted by copyright worldwide. This shall include making the material available under any licence that IOP deems appropriate for purposes including the maximisation of visibility and the long-term preservation of the content.

1.4 IOP shall process and publish the personal data of each Named Author, as that data is displayed on the Article, including the names and affiliations of the Named Authors and the email address of the Submitting Author, wherever IOP chooses to display it, whether themselves or via a third party, to provide a lasting record of publication and for archiving purposes in the public interest. IOP will process the personal data of Named Authors in accordance with its privacy policy, the current version of which can be accessed via its website.

Representations and warranties

2.1 The Copyright Owner and/or the Submitting Author and/or the US Government Signatory on behalf of the Named Authors and/or the US Government (as appropriate) represent and warrant that with regard to the Article:

2.1.1 it is the original work of the Named Authors;

2.1.2 it has not been published previously in any form, other than in accordance with IOP's [Preprint pre-publication policy](#);

2.1.3 each of the Named Authors has made a material contribution to its conception and/or writing,

has received the final version, has agreed to its submission on these terms and takes responsibility for it and submission has been approved as necessary by the authorities at the establishment where the research was carried out;

2.1.4 the Submitting Author completes and returns this agreement as authorised agent for and on behalf of all the Named Authors and the Copyright Owner (as applicable) and has the full power to enter into it and to make the grants and assignments and/or licences it contains;

2.1.5 the US Government Signatory (where applicable) completes and returns this agreement for and on behalf of the US Government and all the Named Authors who are employees of the US Government and has the full power to enter into this agreement and to make the grants it contains;

2.1.6 it has not been and shall not be submitted to another publisher prior to withdrawal or rejection by IOP;

2.1.7 it does not infringe any third party rights, contains nothing libelous or unlawful, all factual statements are to the best of the Named Authors' knowledge and belief true or based on valid research conducted according to accepted norms and all required permissions have been obtained in writing;

2.1.8 it expressly acknowledges any third-party funding and/or potential conflicts of interest; and

2.1.9 any supplementary material or video abstract is the original work of the Named Authors, or the property of the Copyright Owner, or permission has been obtained from its owner(s) for its publication by IOP and permission has been obtained for the inclusion of any third-party content.

2.2 The Named Authors and/or the Copyright Owner (as appropriate) indemnify and shall keep indemnified IOP against all costs and expenses suffered or incurred by IOP as a result of and/or arising out of any breach of the representations and/or warranties in this section 2.

Miscellaneous

3.1 To the extent that there are moral rights in the Article, all the Named Authors expressly reserve and assert their moral rights to be identified as the authors.

3.2 The Named Authors and/or the Copyright Owner and/or the US Government Signatory on behalf of the US Government shall execute such further documents, and take such actions and do such things, as may be requested by IOP at IOP's reasonable expense to give full effect to the terms of the agreement.

3.3 The grants and assignment or licence in this agreement shall become effective only upon acceptance of the Article for publication. If the Article is withdrawn prior to acceptance, or is rejected, this agreement shall have no effect and no party shall be bound by it.

Confirmation

4.1 By selecting to publish on a subscription basis, the Submitting Author shall ensure that, where relevant, all Named Authors who are affiliated to a university/institution which has an open access policy incompatible with IOP's green open access policy, obtain a waiver for the Article from that open access policy and retain it as evidence of compliance. These Named Authors shall obtain such waivers and provide them to IOP promptly on request. By selecting to publish Gold Open Access, the Submitting Author is responsible for ensuring that the Article Publication Charge of the Journal is paid in full to IOP, pursuant to IOP's payment terms, unless otherwise agreed in writing with IOP.

4.2 By typing the Submitting Author's name into the box at Part 3 below and clicking "Submit", the Named Authors agree to the terms. Where the Article was created as part of a work for hire and/or as part of a Named Author(s)' employment, the Authorised signatories of any third party Copyright Owner(s) and/or the Submitting Author agree, on behalf of such Copyright Owner(s), to these terms by typing the Copyright Owner's name into the "Copyright Owner" box at the top of the page.

Part 4: Confirmation and Execution

Please tick the appropriate boxes in section A, section B and section C below. For help on this section, click [here](#).

req Section A

Please tick one of the boxes below to confirm how you would like the Article published (if it is accepted):
Subscription – Parts 1 and 3 Apply

req Section B

Please tick one of the boxes below to confirm your choice. For help on this section, [click here](#).

For Subscription - Please tick this box to confirm that each Named Author, who is affiliated to a university/institution which has an open access policy incompatible with IOP's green open access policy, has obtained a waiver for the Article from that open access policy. For more information refer to this [page](#).

req Section C

Please ALSO tick one of the boxes below to confirm the basis upon which you are granting IOP the right to publish the article (if it is accepted). For help on this section, [click here](#).

Standard transfer of copyright (assignment) – please select this box for subscription articles unless one of the exceptions below applies.

req Type your name here:


Dr. Heri Sutanto (The "Submitting Author")

req Date:

20-Jan-2020




By clicking "Submit" and typing your name above, you shall be assumed to have read and understood all of the terms and conditions of the relevant part of this agreement and you will be agreeing to all of the terms and conditions and assignment (as the case may be) detailed above.

LAST UPDATED October 2019

This site uses cookies. By continuing to use this site you agree to our use of cookies. To find out more, see our [Privacy and Cookies policy](#). 

ACCEPTED MANUSCRIPT

An artifact-free thyroid shield in CT examination: a phantom study

Heri Sutanto¹ , Yulia Irdawati², Choirul Anam³ , Toshioh Fujibuchi⁴, Geoff Dougherty⁵, Eko Hidayanto⁶ , Zaenal Arifin⁷, Johni Wahyuadi Soedarsono⁸ and Bahruddin .⁹

Accepted Manuscript online 22 January 2020 • © 2020 IOP Publishing Ltd

What is an Accepted Manuscript?

herisutanto@live.undip.ac.id

¹ Physics, Universitas Diponegoro, Jl. Prof.SOedarto, SH-Tembalang, Semarang, 50275, INDONESIA

² Diponegoro University Faculty of Science and Mathematics, Semarang, Jawa Tengah, INDONESIA

³ Department of Physics, Universitas Diponegoro, Jl. Prof Soedarto, Tembalang, Jl. Prof Soedarto, Tembalang, Semarang, Central Java, 50275, INDONESIA

⁴ Department of Health Sciences, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Fukuoka 812-8582, Japan, Fukuoka, JAPAN

⁵ Applied Physics and Medical Imaging, California State University Channel Islands, Camarillo, CA 93012, USA., Camarillo, California, UNITED STATES


⁶ Physics, Universitas Diponegoro, Semarang, Jawa Tengah, INDONESIA


⁷ Physics, Diponegoro University Faculty of Science and Mathematics, Semarang, Jawa Tengah, INDONESIA

⁸ Department of Metallurgical and Materials Engineering, University of Indonesia, Depok, Jawa Barat, INDONESIA

⁹ Chemical Engineering, Riau University, Pekanbaru, Riau, INDONESIA

Heri Sutanto  <https://orcid.org/0000-0003-3404-0337>

Choirul Anam  <https://orcid.org/0000-0003-0156-6797>

Eko Hidayanto  <https://orcid.org/0000-0002-3438-0369>

Received 13 November 2019

Revised 17 January 2020

Accepted 22 January 2020

Accepted Manuscript online 22 January 2020

Method: Single-blind

Revisions: 1

Screened for originality? Yes

<https://doi.org/10.1088/2057-1976/ab6ed1>

Abstract

Synthetic thyroid shields based on silicon rubber (SR)–lead (Pb) composites was evaluated and compared to a tungsten paper (WP) and a radibarrier thyroid shields in CT examination of the neck. Reduction of thyroid doses and the resulting image qualities were assessed in this study. The SR-Pb thyroid shield with a variation percentage of Pb from 0 to 5 wt% has a thickness of 0.6 cm. Scanning on the neck of an anthropomorphic phantom was performed with and without the SR-Pb, WP, and radibarrier thyroid shields. The thyroid shields were placed directly on the neck surface. The thyroid dose was measured using radio photo-luminescence (RPL) detectors. The image quality was characterized by consistency of the Hounsfield unit (HU) values and its standard deviation on the areas of anterior, posterior and lateral of the neck phantom. Detail evaluation of the image quality was employed by image subtraction. It is found that surface of thyroid dose decrease with the increase of Pb percentage in the SR-Pb shield. The thyroid dose reduction is 34% for Pb percentage of 5 wt%. The reduction of thyroid dose using WP and radibarrier are 36% and 67%, respectively. It is clear that the thyroid dose

reduction when using the WP and radibarrier is higher than when using SR-Pb 5 wt% thyroid shield. However the existence of artifact in the WP and the radibarrier deteriorates the image quality, indicated by a significant change of HU value, i.e. the increases of HU in posterior area are 77% for the WP and 553% for the radibarrier, while using the SR-Pb shield the resulting image has very light artifact, marked by only small increase of the HU value before and after using SR-Pb shield, i.e. the increase of HU in the posterior area is only 9%.

Export citation and abstract

BibTeX

RIS



As the Version of Record of this article is going to be/has been published on a subscription basis, this Accepted Manuscript will be available for reuse under a CC BY-NC-ND 3.0 licence after a 12 month embargo period.

Although reasonable endeavours have been taken to obtain all necessary permissions from third parties to include their copyrighted content within this article, their full citation and copyright line may not be present in this Accepted Manuscript version. Before using any content from this article, please refer to the Version of Record on IOPscience once published for full citation and copyright details, as permission may be required. All third party content is fully copyright protected, unless specifically stated otherwise in the figure caption of the Version of Record.

Access this article

Login options

Individual login

or

Institutional login
via Athens/Shibboleth

The computer you are using is not registered by an institution with a subscription to this article. Please log in below. Find out more about journal subscriptions at your site.

Make a recommendation

[Recommend this journal](#)

To gain access to this content, please complete the Recommendation Form and we will follow up with your librarian or Institution on your behalf.

Subscribe to this journal